Bottom line is they didn't accrue occult patients in phase 2. Why would anyone care if the imaging info wouldn't be available? Imaging wasn't thee primary endpoint visual acuity was.
David Guyer is great at making excuses. I asked him a simple question at a conference once. I asked him why he did not enroll diabetics into his trial? At least 20 percent of wet AMD patients have diabetes. That is a big piece of the market to ignore. David Guyer's answer was that it is very rare for a patient with wet AMD to also have diabetic retinopathy. That wasn't my question.
there is nothing to argue about. the data will be out by the end of the month. I am glad I brought the company to the attention of the board. It allows them to do the due diligence on the company should they choose to do so.
Feuerstein and you believe it is a scam. That is fine, we will know shortly. looking at the data from the first 60 patients I feel good about its chances. Cowen released a nice report on Ohr today. They are somewhat biased because they banked the raise a few weeks ago, but they have a good reputation and probably would not have done the raise if they thought the drug was worthless.
Jason Slakter, one of the top retina specialists in the country, and the company CMO put 200 k of his own money into the deal. If he did not think it would work why would he do that knowing the data would be coming out a month later, and he would not be able to trade out of it.
You are a bright guy but you aren't right of all the time.
